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While the world’s attention is riveted on the search for a COVID-19 vaccine, we must 
not lose sight of the pandemic’s impact on the prevention of other vaccine-preventable 
diseases (VPD). The reduction in morbidity and mortality from infectious disease is tru-
ly one of public health’s greatest accomplishments. [1] Advances in molecular biology 
have expanded the pool of vaccine platforms and worldwide research efforts towards a 
COVID-19 vaccine have already produced multiple vaccine candidates leading to several 
ongoing clinical trials. [2] In the meantime, other pathogens have not vanished as the 
world’s attention is diverted elsewhere.
 
The risk of resurgent COVID-19 through summer and into the fall and winter season 
remains high, in the face of economic and political pressures to open up nations under 
virtual lockdown. It is certain that influenza will reappear in the Northern Hemisphere 
by the end of 2020. Questions to be asked prospectively include:  Will there be enough 
influenza vaccine available and will the means to deliver the vaccine exist when influen-
za season returns? The World Health Organization published its recommendations for 
the composition of the 2020-21 influenza vaccine on February 28, 2020. [3] Will produc-
tion of adequate amounts of influenza vaccine be possible as multiple companies focus 
on COVID-19 vaccine? Will the healthcare system be ready to vaccinate for influenza if a 
surge of new COVID-19 cases occurs at the same time? Since the clinical presentations of 
COVID-19 and influenza are similar, prevention of influenza is key in reducing diagnos-
tic confusion in the upcoming influenza season. Some evidence from Japan suggests that 
both infections can coexist, providing additional diagnostic and therapeutic confusion. 
[4] 
Hungerford and Cunliffe note that the pandemic will impact VPD in several ways. [5] 
Whereas increased hand hygiene, social distancing, and masking may reduce VPD, a 
negative and more significant impact may be on interruption of vaccination schedules 
in both children and adults. In the United States, children are already missing doses of 
vaccines due to the lockdown. [6] The result of missed doses could well be epidemics of 
measles and diphtheria if the missed doses are not caught up quickly. This impact could 
occur both domestically and internationally. Additionally, programs to eradicate diseas-
es such as polio will be at risk in nations that already have weak public health programs. 
As Hungerford and Cunliffe point out, governments and health agencies must monitor 
other VPD and respond quickly as new outbreaks of those diseases arise.
Finally, evidence is mounting on social media that anti-vaccination groups are actively 
fighting a proposed COVID-19 vaccine. [7] The term vaccine hesitancy has been used 
in an effort to lower tensions between pro and anti-vaccine groups [8]; regardless of the 
term used, failure to deploy vaccines on schedule remains a significant impediment to 
public health and will only increase morbidity and mortality from infectious disease. Re-
jection of an effective COVID-19 vaccine by vaccine hesitant individuals will slow the 
world’s ability to emerge from this pandemic and will amplify social and economic harm 
far beyond what has already occurred. Clinical medicine and public health communities 
must be prepared to deal with the anti-vaccination threat.
As this is being written, we are at the six-month mark of this pandemic. While a laser 
focus is appropriately on development and testing of an effective COVID-19 vaccine, we 
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must not forget about the threat of other VPD. Vaccines are said to save lives but the act of vaccination is a crucial step 
for eradication of infectious disease. An effective vaccine in a vial is of little use until it is administered to a susceptible 
human.
References
1. Centers for Disease Control and Prevention (CDC). Control of infectious diseases. MMWR Morb Mortal Wkly 
Rep. 1999 Jul;48(29):621–9. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm4829a1.htm 
PMID:10458535
2. Lurie N, Saville M, Hatchett R, Halton J. Developing COVID-19 vaccines at pandemic speed. N Engl J Med. 2020 
May;382(21):1969–73. Available from: https://www.nejm.org/doi/full/10.1056/NEJMp2005630 https://doi.
org/10.1056/NEJMp2005630 PMID:32227757
3. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2020 – 2021 
northern hemisphere influenza season [report on the internet]. Geneva: WHO Consultation; 2020 Feb 28 [cited 
2020 May 25]. Available from: https://www.who.int/influenza/vaccines/virus/recommendations/2020-21_north/
en/
4. Azekawa S, Namkoong H, Mitamura K, Kawaoka Y, Saito F. Co-infection with SARS-CoV-2 and influenza A virus. 
IDCases. 2020 Apr;20:e00775. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184249/ https://
doi.org/10.1016/j.idcr.2020.e00775 PMID:32368495
5. Hungerford D, Cunliffe NA. Coronavirus disease (COVID-19) - impact on vaccine preventable diseases. Euro Sur-
veill. 2020 May;25(18): Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219030/ https://doi.
org/10.2807/1560-7917.ES.2020.25.18.2000756 PMID:32400359
6. Santoli JM, Lindley MC, DeSilva MB, Kharbanda EO, Daley MF, Galloway L, et al. Effects of the COVID-19 pan-
demic on routine pediatric vaccine ordering and administration - United States, 2020. MMWR Morb Mortal Wkly 
Rep. 2020 May;69(19):591–3. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/mm6919e2.htm?s_ci-
d=mm6919e2_w https://doi.org/10.15585/mmwr.mm6919e2 PMID:32407298
7. Stanley-Becker I. The Washington Post. Trump’s promise of ‘Warp Speed’ fuels anti-vaccine movement in fer-
tile corners of the web [press release] (2020 May 20) [cited 2020 Jun 26]. Available from: https://www.washing-
tonpost.com/national/trumps-promise-of-warp-speed-fuels-anti-vaccine-movement-in-fertile-corners-of-the-
web/2020/05/20/c2b3d408-9ab2-11ea-89fd-28fb313d1886_story.html 
8. MacDonald NE. SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determi-
nants. Vaccine. 2015 Aug 14;33(34):4161-.
